What are the causes of Group 3 Pulmonary Arterial Hypertension (PAH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Group 3 Pulmonary Hypertension: Causes

Group 3 pulmonary hypertension is caused by chronic lung diseases and/or hypoxia, with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) being the most common etiologies. 1

Primary Causes

According to the 2015 ESC/ERS Guidelines, Group 3 PH encompasses seven distinct categories of lung diseases and hypoxic conditions 1:

Parenchymal Lung Diseases

  • Chronic obstructive pulmonary disease (COPD) - the most frequently encountered cause, though severe PH (mean PAP ≥35 mmHg) occurs in only 1-4% of COPD patients 1, 2
  • Interstitial lung disease - commonly develops mild PH, with severe PH being uncommon 1
  • Combined emphysema/fibrosis syndrome - demonstrates particularly high prevalence of PH compared to isolated COPD or ILD 1, 2
  • Other pulmonary diseases with mixed restrictive and obstructive patterns 1

Hypoventilation and Sleep Disorders

  • Sleep-disordered breathing - nocturnal hypoxemia drives pulmonary vascular changes 1, 2
  • Alveolar hypoventilation disorders - cause PH through chronic hypoxemia and hypercapnia 1

Environmental and Developmental Causes

  • Chronic exposure to high altitude - sustained hypoxic pulmonary vasoconstriction leads to PH 1
  • Developmental lung diseases - congenital abnormalities predispose to PH from early life 1

Pathophysiological Mechanism

The underlying mechanism across all Group 3 causes involves chronic hypoxemia and/or destruction of the pulmonary vascular bed 1. The pathological changes characteristically include:

  • Medial hypertrophy of distal pulmonary arteries 1
  • Intimal obstructive proliferation 1
  • Variable degrees of vascular bed destruction in emphysematous or fibrotic areas 1

Clinical Distinction

Group 3 PH is distinguished from Group 1 (pulmonary arterial hypertension) by the presence of significant underlying lung disease and/or hypoxia as the primary driver. 1 The hemodynamic profile shows pre-capillary PH (mean PAP ≥25 mmHg, pulmonary arterial wedge pressure ≤15 mmHg) in the context of documented parenchymal lung disease or chronic hypoxia 1, 2.

Important Clinical Caveat

In COPD patients with severe PH (mean PAP >40 mmHg), approximately 60% have another potential cause of PH beyond COPD alone, such as anorexigen exposure, connective tissue disease, thromboembolic disease, or left ventricular disease 1. When severe PH is present in the setting of only mild-to-moderate airflow obstruction, alternative diagnoses must be actively excluded.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Group 3 Pulmonary Hypertension: Clinical Examples

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.